ScreenerHero

VRDNViridian Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · viridiantherapeutics.com
24.29USD-2.06%Mkt Cap: 2.75B $P/E: —

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a diff…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.75B $
Enterprise Value2.14B $
Revenue (TTM)71.13M $
Gross Profit-253.55M $
Net Income (TTM)-342.60M $
Revenue/Share0.7360 USD
Last Price24.29 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees252
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.84
PEG—
EV/EBITDA-5.28
EV/Revenue30.04
P/S39.02
P/B4.98
EPS (TTM)-3.36
EPS (Forward)-2.77
52W Range
13.1853% of range34.29
52W High34.29 USD
52W Low13.18 USD
Profitability
Gross Margin0.00%
Oper. Margin-44460.56%
EBITDA Margin0.00%
Profit Margin-483.57%
ROE-47.44%
ROA-38.09%
Growth
Revenue Growth278.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-276.39M $
CapEx (TTM)495.00K $
FCF Margin-387.33%
FCF Yield-10.01%
Net Debt-736.80M $
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity0.07
Current Ratio16.95
Quick Ratio16.56
Book Value/Sh4.919 USD
Cash/Share8.664 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 13, 2020
Splits
Last Split1:15
Split DateNov 13, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.63 USD
Upside (mean)+50.8%
Target Range22.00 USD – 50.00 USD
$22.00+50.8% to mean$50.00
# Analysts16
Ownership
Shares Out.113.29M
Float106.51M
Insiders0.17%
Institutions123.79%
Short Interest
Short Ratio10.1d
Short % Float17.60%
Short % Out.16.99%
Shares Short19.23M
Short (prev mo.)17.34M
Technical
SMA 5019.58 (+24.1%)
SMA 20023.97 (+1.3%)
Beta0.94
S&P 52W Chg18.16%
Avg Vol (30d)1.78M
Avg Vol (10d)1.82M
Technical Indicators
RSI (14)69.0
MACD1.3270
MACD Signal1.1114
MACD Hist.+0.2157
BB Upper25.23 USD
BB Middle21.45 USD
BB Lower17.66 USD
BB Width35.30%
ATR (14)1.016 USD
Vol Ratio (20d)0.47x